FMA
ALXN

FNY Managed Accounts’s Alexion Pharmaceuticals ALXN Stock Holding History

FNY Managed Accounts’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$45K Buy
+408
New +$48.8K 0.05% 88

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FNY Managed Accounts's ALXN Position: Q1 2018 in Review

FNY Managed Accounts opened a new position in Alexion Pharmaceuticals (ALXN) in Q1 2018: 408 shares worth $45K. The stake represents 0.05% of the portfolio and ranks #88 among its holdings.

596 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • FNY Managed Accounts held 408 shares of Alexion Pharmaceuticals worth $45K as of Q1 2018.
  • Alexion Pharmaceuticals was a new FNY Managed Accounts position in Q1 2018.
  • Alexion Pharmaceuticals made up 0.05% of FNY Managed Accounts's portfolio in Q1 2018, its #88 holding.
  • 596 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.